All of the ESRs recruited by PET3D will be exposed to a variety of highly complementary research environments spanning different therapeutic areas: oncology, cardiovascular, neuroscience and all of the ESRs will spend at least one secondment in a different country and will have the opportunity to attend training events and consortium meetings in all of the 7 countries involved in PET3D.


Each ESR will be exposed to the following:

  • Cutting edge research training, technical training, generic skills training.
  • Cross-sectorial training – translational skills training, commercialisation.
  • Access to state of the art technologies in each of the beneficiary sites.
  • Transferrable and generic skills training – communications, presentation, writing, management, dissemination, intellectual property rights protection, dissemination and exploitation, ethical issues, entrepreneurial initiatives, CV writing and interview training available locally at each beneficiary site.
  • Strong collaborative bonds with each ESR, with supervisors and mentors and also with researchers in related fields, thereby laying the foundation for future continued European-wide research collaboration.


ESR1 - Host ABD

AZ, May 2018, for 6 months,
For in vitro and ex-vivo profiling, and pharmacokinetic studies on 3H/14C versions of fatty acid analogues and CPT1 inhibitors.

ESR2 - Host ABD

AMS, month 30, for 3 months,
‘for exploring full antibody or nanobody versions of the tracer.

ESR3 - Host AMS

1. BER, month 9, for 3 months,
for design and synthesis of target compounds.

2. IMA, month 18, for 6 months,
for performing chemistry and animal studies, development of complementary skills (e.g. business, project management).

ESR4 - Host AMD

1. ABD, month 26, for 6 months,
for evaluation of clearing agent on in vivo behaviour proteins and peptides.

2. BRU, month 33, for 2 months,
for comparing BRU’s nanobody technology products to come to best practice.

ESR5 - Host BRU

1. ABD, month 7, for 4 months
to gain knowledge on 18F-FDR radiochemistry

2. IMA, month 24, for 6 months,
for GMP production, toxicity study, IMPD writing, training on IP.

ESR6 - Host BRU

AZ, November 2018, for 6 months,
translational pre-clinical studies on radioisotope- and NIR-labelled nanobodies.

ESR7 - Host SAN

1. ABD, May 2018, for 4 months,
to gain knowledge on pre-targeting strategies and related synthetic chemistry.

2. IMA, June 2019, for 4 months,
to acquire skills in image quantification and kinetic modeling.

ESR8 - Host SAN

1. BRU, month 16, for 2 months,
to gain knowledge on nanobody technology.

2. AZ, month 28, for 6 months,
to bind an oncology compound from AstraZeneca to the NanoBite platform.

ESR9 - Host BER

AZ, month 18, for 6 months,
for biodistribution studies through micro-dosing and drug validation studies.

ESR10 - Host BER

IMA, month 29, for 6 months
for performing biodistribution studies and metabolite characterisation.

ESR11 - Host MUN

IMA, month 12, for 6 months
to study therapeutic modulation of neuroinflammation via pre-clinical PET imaging.

ESR12 - Host MUN

AZ, month 6, for 6 months
to study best modality of therapeutic intervention (e.g. anti-angiogenesis).

ESR13 - Host ABD

AMS, month 24, for 6 months
for performing PET imaging studies on pre-targeted click tracers.

ESR14 - Host IMA

1. BER, month 13, for 3 months
for studying a pre-targeted approach to hypoxia PET imaging.

2. MUN, month 25, for 3 months
for exploring a pre-targeted PET imaging approach to gliomas.

3. ICL, month 8 and month 20 for 2 months each
characterisation of the constructs.

ESR15 - Host AZ

ABD, September 2018, for 6 months
to develop a [18F]-labeled tracer and perform pre-clinical studies in vivo.


In addition to local training, this ETN offers cutting-edge Network-wide training opportunities, see overview in ‘Main Network Training Events & Conferences’.

Dissemination events are public conferences or symposia on:

  • hot scientific topics of interest to PET3D
  • transferrable skills/employability workshops
  • business-related events

These events will be of particular interest to radiopharmaceuticals/drug discovery stakeholders and students.

Schools are larger and structured training initiatives lasting from 2 days to 5 days.

Activity Structure Month/Duration/Location/ECTS Main Organisers/lecturers
School in Radiopharmaceutical development • 10 lectures of 2hr • 3 days experimental • Written exam Month 7 / 5 days Amsterdam/ 2.5 ECTS Prof. A.D. Windhorst (Chair and organiser), Dr D.J. Vugts, Prof G.A.M.S. van Dongen
School in Radiopharmaceuticals in Drug Discovery • 6 lectures of 2 hr • Overview of Drug discovery & development process • Tour of site & exemplary drug discovery project Month 13 /2 days AstraZeneca site Mölndal / 1 ECTS Chair and Organiser: Dr. C. S. Elmore (AZ); Lecturers: Dr. J. Passchier (IMA). Lectures from Advisory Board members
School in Nanobody Theranostics • Intensive program on molecular imaging with • 9 Lectures and • Hands-on practical training • Round table discussion Month 25/ 4 days / Brussels/ 2 ECTS Chair and Organiser: Prof. V. Caveliers (BRU). Lecturers: Dr. T. Lahoutte (BRU), Dr. N. Devoogdt (BRU), Dr. M. R. Zalutsky (Duke University, USA), Dr. V. Caveliers (BRU), Dr. C. Xavier (BRU), Dr. S. Hernot (BRU), Dr. S. Muyldermans (BRU).
School in Pre-clinical imaging • In-depth training on state-of-the-art molecular imaging with • 6 plenary lectures of 2 hr and • 7 hands-on sessions on a broad spectrum of dedicated imaging technologies including μPET, μSPECT, μCT, μMRI, and optical imaging. Month 36/ 5 days/ Muenster/ 2.5 ECTS Chair and Organiser: Prof. A. Jacobs (MUN)

Training events are smaller, 1-day training courses/workshops, which will be open to external participants and therefore will also represent dissemination opportunities.




PhD Ilaria Patruno was...

First PET3D PhD

Markus Artelsmair successfully...

Outreach at CIC BiomaGUNE

25 Students from Tolosako Inmakulada Lanbide...

Dissemination Video Jessica Bridoux

PET imaging and therapy - outline of theranostic...

PET3D Manuscripts published 2018

Synthesis of C-14 Labeled GABAA α2/α3 Selective...

IMPACT Article Published

    Link to ingentaconnect article.   The ESRs...



PET3D Final Public Conference 28 May 2020

PET3D  Conference cancelled due to COVID-19...

A market model for PET imaging – Open Symposium 4 April 2019

Expertise line up at International Symposium...

S4- School ‘Preclinical Imaging’ Muenster 4 – 9 Nov. 2018

9th Mouse Imaging Academy (MIA) 05-09 November...

Mid-Term Meeting

08 June  2018 PET3D Mid term meeting  ...

S1 – School on ‘Radiopharmaceutical Development’

27 February - 03 March 2017 PET3D 5-day training...